Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years
Authors not listed
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 2020
Abstract
A total of 900 subjects are planned to be randomly divided into 2 doses of low-dose experimental vaccine group, 2 doses of high-dose experimental vaccine group, 2 doses of placebo group, 3 doses of low-dose experimental vaccine group, 3 doses of high-dose experimental vaccine group and 3 doses of placebo group, the sample size of each group was 150 cases.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-25 MST
Cite this
APA
Anonymous. (2020). A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years. <em>Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.</em>. https://clinicaltrials.gov/study/NCT04466085
Vancouver
Anonymous. A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.. 2020.
BibTeX
@misc{anon2020ARando,
title = {A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years},
author = {Anonymous},
journal = {Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.},
year = {2020},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
National Vaccine and Serum Institute, China 2022
Open access · US-GOV
A Randomized, Controlled Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell) in Population Aged 18 Years and Above
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. 2020
Open access · US-GOV
A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of Recombinant New Coronavirus Vaccines (CHO Cells) in Healthy People Aged 60 Years and Above
National Vaccine and Serum Institute, China 2021
Open access · US-GOV
Phase I/II Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy People Aged 3 Years and Older
National Vaccine and Serum Institute, China 2022
Open access · US-GOV
Phase I Clinical Trial of Safety, Tolerance and Immunogenicity of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above
MAXVAX Biotechnology Limited Liability Company 2022
Open access · US-GOV
A Phase I, Single Center, Randomized, Blinded, Controlled Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above
Sinovac Biotech Co., Ltd 2026
Open access · US-GOV